You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

171 Results
Guidelines and Advice
Status: Current
Version: 1
Aug 2019
Guidelines and Advice
Status: Current
ID: GL-C50-09
Jun 2019
Guidelines and Advice
Status: Current
Mar 2019
Guidelines and Advice
Status: Current
ID: GL 3-20
Version: N/A
Aug 2019
Guidelines and Advice
Status: In-Review
ID: 4-8
Version: 4
Jul 2019
Guidelines and Advice
Status: Current
Version: 1
Aug 2019
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
ID: GL 17-12
Version: N/A
Sep 2019
Guidelines and Advice
Status: Current
ID: ES SMG-3
Jan 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - Maintenance Treatment for Refractory Follicular Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2019
Regimen
Cancer Type:
Genitourinary, 
Testis
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
bleomycin,
etoposide,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
prednisone,
vinCRIStine,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019

Pages